Skip to main content
. 2022 Aug 12;13(9):1510–1516. doi: 10.1021/acsmedchemlett.2c00309

Table 2. Additional Miscellaneous SAR.

graphic file with name ml2c00309_0005.jpg

compda R1 R2 X Y IC50 (μM)b
24 NHCO2tBu H CH CH 0.262 ± 0.039
45 H H CH CNHCO2tBu 11.06 ± 0.33
46 NHCO2tBu H CH N 0.309 ± 0.010
47 NHCO2tBu H N CH 0.372 ± 0.038
48 NHCO2tBu Mec CH CH 0.0274 ± 0.0012
49 NHCO2tBu Phec CH CH 0.172 ± 0.075
50 NHCO2iPr Mec CH N 0.002 ± 0.001
51 oxazolidinone H CH CH 5.16 ± 0.07
52 CO2H H CH CH inactive
53 CO2Me H CH CH 1.64 ± 0.27
54 CO2iPr H CH CH 0.110 ± 0.049
55 OCOiPr H CH CH 5.45 ± 0.23
56 CONMe2 H CH CH 5.91 ± 0.27
57 CONHtBu H CH CH inactive
a

All compounds are racemates.

b

IC50 values represent the half maximal (50%) inhibitory concentration for the Bcl-2–Beclin 1 BH3 interaction as determined in the AlphaLISA assay. Error represents SD (n = 3). All compounds were inactive (at 10 μM) against the Bcl-2–Bax BH3 interaction except compounds 50 (IC50 = 0.157 ± 0.048 μM) and 54 (IC50 = 4.36 ± 0.03 μM).

c

Single diastereomer; configuration not assigned.